Suthira Taychakhoonavudh1, Woralak Chumchujan1, Raymond Hutubessy2, Nathorn Chaiyakunapruk3,4. 1. Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University , Bangkok, Thailand. 2. Immunization, Vaccines and Biologicals (IVB) Department, World Health Organization , Geneva, Switzerland. 3. Department of Pharmacotherapy, College of Pharmacy, University of Utah , Salt Lake City, UT, USA. 4. School of Pharmacy, Monash University Malaysia , Bandar Sunway, Malaysia.
Abstract
Over the past few years, many innovative vaccines became available that offer protection for diseases which have never been prevented before. While there are several factors that could have an impact on access, the use of health technology assessment (HTA) undoubtedly is also one of the contributing factors. Objectives: To explore the landscape of vaccine access and the role of HTA in new vaccine adoption in Association of Southeast Asian Nations (ASEAN) countries. Results: A great deal of progress has been made in terms of access to new and innovation vaccine in the region. Variation in access to these vaccines comparing between countries, however, is still observed. The use of HTA in supporting new vaccine adoption is still in an early stage especially in Gavi, the Vaccine Alliance-eligible countries. Conclusions: Improving the use of HTA evidences to support decision making could accelerate the efficient adoption of new vaccine in ASEAN region.
Over the past few years, many innovative vaccines became available that offer protection for diseases which have never been prevented before. While there are several factors that could have an impact on access, the use of health technology assessment (HTA) undoubtedly is also one of the contributing factors. Objectives: To explore the landscape of vaccine access and the role of HTA in new vaccine adoption in Association of Southeast Asian Nations (ASEAN) countries. Results: A great deal of progress has been made in terms of access to new and innovation vaccine in the region. Variation in access to these vaccines comparing between countries, however, is still observed. The use of HTA in supporting new vaccine adoption is still in an early stage especially in Gavi, the Vaccine Alliance-eligible countries. Conclusions: Improving the use of HTA evidences to support decision making could accelerate the efficient adoption of new vaccine in ASEAN region.
Keywords:
ASEAN; Vaccine; access; expanded program in immunization; health technology assessment; national immunization program
Authors: K B Phua; F S Lim; Y L Lau; E A S Nelson; L M Huang; S H Quak; B W Lee; Y L Teoh; H Tang; I Boudville; L C Oostvogels; P V Suryakiran; I V Smolenov; H H Han; H L Bock Journal: Vaccine Date: 2009-08-11 Impact factor: 3.641
Authors: M Y Rohani; A Raudzah; A J Ng; P P Ng; A A Zaidatul; I Asmah; M Murtaza; N Parasakthy; M Y Mohd Yasmin; Y M Cheong Journal: Epidemiol Infect Date: 1999-02 Impact factor: 2.451
Authors: Paul Turner; Phana Leab; Sokeng Ly; Sena Sao; Thyl Miliya; James D Heffelfinger; Nyambat Batmunkh; Fernanda C Lessa; Jenny A Walldorf; Terri B Hyde; Vichit Ork; Md Shafiqul Hossain; Katherine A Gould; Jason Hinds; Ben S Cooper; Chanpheaktra Ngoun; Claudia Turner; Nicholas P J Day Journal: Clin Infect Dis Date: 2020-04-10 Impact factor: 9.079
Authors: Philip Eng; Lean Huat Lim; Chian Min Loo; James Alvin Low; Carol Tan; Eng Kiat Tan; Sin Yew Wong; Sajita Setia Journal: Int J Gen Med Date: 2014-03-31